Galapagos NV (NASDAQ:GLPG) Given Consensus Rating of “Reduce” by Analysts

Galapagos NV (NASDAQ:GLPG) has been given an average rating of “Reduce” by the five ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $31.00.

A number of equities analysts recently weighed in on the company. Leerink Partnrs raised Galapagos to a “hold” rating in a research note on Monday, September 9th. Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd. Finally, Leerink Partners started coverage on shares of Galapagos in a research report on Monday, September 9th. They issued a “market perform” rating and a $24.00 price target for the company.

Hedge Funds Weigh In On Galapagos

A number of large investors have recently made changes to their positions in the business. Headlands Technologies LLC grew its position in Galapagos by 949.3% during the first quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 712 shares in the last quarter. Barometer Capital Management Inc. acquired a new position in shares of Galapagos in the fourth quarter worth $122,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Galapagos by 66.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 3,769 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 1,504 shares in the last quarter. Signaturefd LLC boosted its position in Galapagos by 48.1% during the second quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 1,258 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 814 shares in the last quarter. Institutional investors and hedge funds own 32.46% of the company’s stock.

Galapagos Stock Performance

Shares of NASDAQ GLPG opened at $29.19 on Friday. The stock’s fifty day simple moving average is $27.68 and its 200 day simple moving average is $28.11. Galapagos has a 52-week low of $24.16 and a 52-week high of $42.46.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.